Most people who search “melanotan 2 before and after” are hoping to find side-by-side transformation photos: pale skin on the left, a deep tan on the right. It is worth being direct about what this page is and is not. dosagepeptide.com is a research-use-only dosage reference. We do not publish before/after photos, user testimonials, or promised results for Melanotan II (MT-II), because that kind of content cannot be verified and is easy to stage. Instead, here is what the peer-reviewed literature and clinical-trial registries actually document about MT-II over time — including how thin that evidence really is.
What the research shows over time
The honest headline finding is that human data on Melanotan II specifically is extremely limited. The only published human tanning trial of MT-II is a pilot Phase I study in just three male volunteers (Dorr et al., 1996). Subcutaneous MT-II given on weekdays for two weeks produced increased pigmentation of the face, upper body, and buttocks — measured by quantitative reflectance and visual inspection about one week after dosing ended — alongside side effects including fatigue, mild nausea, and spontaneous erections (Dorr et al., 1996).
The more rigorous tanning trials in this field studied a closely related but different compound, Melanotan-I (NDP-α-MSH, the parent of the licensed drug afamelanotide) — not MT-II. A double-blind, placebo-controlled RCT in 28 men found that skin darkening peaked one to three weeks after a 12-day injection course, with no darkening in the placebo group (Levine et al., 1991). Later Melanotan-I studies showed the same delayed, transient pattern and confirmed a real rise in skin eumelanin by HPLC (Ugwu et al., 1997; Dorr et al., 2000).
| Study | Compound | Design / size | Measured outcome & timing |
|---|---|---|---|
| Dorr et al., 1996 (Life Sciences) | Melanotan II | Phase I pilot, n=3 | Increased facial/upper-body pigment by reflectance ~1 week after a 2-week course |
| Levine et al., 1991 (JAMA) | Melanotan-I (NDP-MSH) | Double-blind RCT, n=28 | Skin darkening peaked 1–3 weeks after a 12-day course; none with placebo |
| Ugwu et al., 1997 (Biopharm Drug Dispos) | Melanotan-I | Crossover PK, n=3 | Tanning peaked ~1 week, still visible 3 weeks after 10 doses |
| Dorr et al., 2000 (Photochem Photobiol) | Melanotan-I | n=7 | Skin eumelanin +49% (forehead) to +98% (forearm) at ~1 week post-course |
It is important to separate the tiers of evidence. The clinical human tanning data above is small, decades old, and mostly about Melanotan-I. Preclinical MT-II research exists but studies unrelated endpoints in animals — appetite in mice, erection in rats, thermogenesis, and behavior — not cosmetic “transformations.” Anecdotal reports come from online-forum and interview studies, where users self-report skin darkening but also widespread misinformation and unregulated dosing (Gilhooley et al., 2021). On ClinicalTrials.gov, there are essentially no completed registered MT-II tanning trials; the active registered program uses afamelanotide (from Melanotan-I) for medical conditions such as erythropoietic protoporphyria and vitiligo, and a single MT-II vitiligo study (NCT07437560) is only slated to begin in 2026 with no results yet.
Realistic expectations
What the data does support: short courses of subcutaneous melanocortin peptides can measurably darken skin in small studies, the effect is delayed (it often peaks after dosing stops), and it is transient, fading over subsequent weeks. What the data does not support: any controlled evidence on long-term or repeated MT-II use, any standardized “level of tan” you can expect, or proof that MT-II is a safe substitute for sun exposure. Response also varies by baseline skin type — the RCT found different darkening curves for lighter versus darker skin types (Levine et al., 1991).
This is exactly why online “before and after” photos are unreliable for a research compound like MT-II. They have no controls or standardized lighting, they are subject to selection bias (only flattering results get posted), the product itself is unregulated and of unknown purity and dose, and users frequently combine MT-II with sunbeds or sun exposure — documented in the case literature — so the photo may show ultraviolet tanning, not the peptide. Critically, MT-II also darkens existing moles, which can mask — or be confused with — the very changes that signal skin cancer.
The Timeline: What Actually Happened, and When
The single most useful thing the trials give you is timing — and it does not match how melanocortin peptides are usually described. Skin darkening in these studies was delayed: it kept building after the injections stopped, then faded. Side effects, by contrast, showed up during dosing.
| When | What was measured | Study |
|---|---|---|
| Days 1–14 (during a short course) | Side effects appear first — fatigue, mild nausea, spontaneous erections. Pigment change is under way but not at its peak. | Dorr et al., 1996 (MT-II, n=3) |
| ~1 week after the last dose | Measurable darkening of face, upper body and buttocks by reflectance; skin eumelanin up 49% (forehead) to 98% (forearm) | Dorr 1996; Dorr et al., 2000 (MT-I) |
| 1–3 weeks after the course | Darkening peaks — after dosing has stopped. No change in the placebo group. | Levine et al., 1991 (MT-I RCT, n=28) |
| ~3 weeks after | Still visible, clearly fading | Ugwu et al., 1997 (MT-I) |
| Beyond a few weeks | No controlled data exists. Nothing published follows repeated or long-term courses of MT-II. | — |
Two caveats that matter more than the table. First, the only human MT-II tanning study had three participants; the better-designed trials studied Melanotan-I, a different molecule. Second, the trials used measured, standardized subcutaneous doses of characterized material — not an unregulated vial of unknown content. Neither the timing nor the magnitude transfers cleanly to what people buy online.
Does Skin Type Change the Result?
Yes, and this is one of the few places the data is unambiguous. The placebo-controlled Melanotan-I trial found different darkening curves for lighter versus darker baseline skin types (Levine et al., 1991) — people who already tan easily darkened more readily. That is consistent with the mechanism: these peptides push melanocytes to make more eumelanin through the MC1R pathway, so they amplify a capacity that is already there rather than creating one. It also means that any single “expected result” quoted online is meaningless without stating the baseline skin type, which those posts almost never do.
Nasal Spray vs Injection
Every published human tanning study of a melanocortin peptide used subcutaneous injection. There is no published human trial of intranasal Melanotan II at all. That is a real gap, not a technicality: nasal absorption of a peptide is incomplete and highly variable, so the dose that actually reaches circulation from a spray is unknown and inconsistent between users and between doses. Nasal products are frequently marketed as the “safer” option, but no study has compared them for either effect or safety. Unknown delivered dose is not the same thing as a lower dose.
How Long Does It Last After Stopping?
In the studies, fading began within weeks of the last injection, in line with normal skin-cell turnover replacing pigmented cells. Melanotan-I work found tanning still visible about three weeks after a ten-dose course, past its peak (Ugwu et al., 1997). Beyond that window there is simply nothing published — no trial has tracked how long pigmentation persists after repeated courses, and no trial has tracked what happens to moles after they darken, which is the change with real clinical consequences.
Safety & legal status
Melanotan II is not approved by the FDA (or EMA) for any use and is sold as an unlicensed “research chemical” (Evans-Brown et al., 2009). The documented safety signals are serious even though they come mostly from individual case reports:
- Kidney injury: renal infarction and prior reports of rhabdomyolysis and renal failure (Peters et al., 2020).
- Systemic toxicity: sympathomimetic excess and rhabdomyolysis after injection (Nelson et al., 2012).
- Melanoma / changing moles: cutaneous melanoma reported in MT-II users (Hjuler & Lorentzen, 2014; Paurobally et al., 2011).
- Priapism: prolonged, painful erection requiring emergency treatment (Dreyer et al., 2019; Devlin et al., 2013).
Commonly self-reported effects include nausea, facial flushing, appetite suppression, spontaneous erections, and darkening of moles and freckles. Because supply is unregulated, additional hazards include contaminated or mislabeled product and non-sterile self-injection (Gilhooley et al., 2021). None of this is medical advice; peptides referenced here are for laboratory research use only.
Dosage reference
For research documentation purposes only, our Melanotan II dosage chart summarizes reconstitution and the low milligram-per-dose ranges used in the published literature. You can also work reconstitution math with our peptide dosage calculator. These tools are provided as a reference for researchers and do not constitute a recommendation to use MT-II in humans.
FAQ
Are there real before/after photos in the research?
No. There is no published clinical transformation-photo series for MT-II. The one human MT-II tanning trial measured pigment instrumentally (by reflectance) in three people rather than presenting marketing-style images (Dorr et al., 1996).
How long until changes appear in studies?
In the small trials available, measurable skin darkening appeared within roughly a week of a short injection course and tended to peak one to three weeks after dosing stopped, then fade. Note that the strongest of this evidence is for the related Melanotan-I, not MT-II (Levine et al., 1991; Ugwu et al., 1997).
Is Melanotan II the same as the approved tanning drug?
No. The melanocortin drug that has actually been approved (afamelanotide / SCENESSE, derived from Melanotan-I) is used for rare light-sensitivity disorders, not cosmetic tanning — and it is a different molecule from the MT-II sold online.
Does it work without sun exposure?
In the placebo-controlled trial, the injected group darkened and the placebo group did not, which points to the peptide itself rather than to sunlight (Levine et al., 1991) — though that study used Melanotan-I. The practical problem is the reverse one: interview and forum studies document that users commonly combine MT-II with sunbeds or sun exposure (Gilhooley et al., 2021), so most “before and after” results you see online cannot be attributed to the peptide at all.
Is the tan permanent?
No. Every study that followed participants past the peak saw the pigmentation fade as skin cells turned over. What may not fade is mole darkening — and that is the change linked to case reports of melanoma in MT-II users.
Does Melanotan II protect against sunburn?
There is no evidence it does, and no trial has tested it as sun protection. Assuming that a chemically induced tan substitutes for sunscreen is not supported by anything in the literature, and the darkening of existing moles actively works against early skin-cancer detection.
Is Melanotan II legal?
It is not approved by the FDA or the EMA for any use, and regulators in several countries have issued warnings about unlicensed products sold online. It is supplied as a research chemical, not a medicine or a cosmetic, and it is not legal to sell for human use.
